A new era in moderate- to- severe Atopic Dermatitis : Using Abrocitinb to get patients on the Right track
In this webinar, a detailed discussion is done on a new era in moderate- to- severe Atopic Dermatitis : Using Abrocitinb to get patients on the Right
Speakers : Dr. Sandipan Dhar ,Dr. Shireen Furtado ,Dr. Ramesh Bhat ,Dr. Debjit Kar ,Dr. Maitreyee Panda
New advances in the management of Atopic dermatitis & role of PDE4 Inhibitor
In this webinar, a detailed discussion is done through the interesting session on the new advances in the management of atopic dermatitis.
Speakers : Dr. Anup Kumar Lahiry ,Dr. Rajetha Damisetty ,Dr. Raghavendra Rao ,Dr. V Anand Kumar ,Dr. C Brijesh Nair
Recommended News For You
Recommended Articles For You
Featured News
Featured Articles
Featured Events
Featured KOL Videos
1.
Patients with chronic myeloid leukemia who take nilotinib are at higher risk for diabetes and hyperlipidemia.
2.
More Data from Population-Based Studies Show CRC Screening Lowers Cancer Death Risk.
3.
What Role Should Genomic Classifier Testing Play in Prostate Cancer?
4.
A new mechanism of radioresistance formation demonstrated in lung adenocarcinoma
5.
Squeezing through tiny blood vessels may trigger melanoma cells to spread
1.
The Future of Cancer Care: Genetics, Support Systems, and Emerging Therapies
2.
Everything You Need to Know About Leiomyomas: A Comprehensive Guide
3.
The Importance of Corrected Calcium Levels in Managing Health Conditions
4.
How Parvovirus B19 Affects Pregnant Women and Their Unborn Babies
5.
Cowden Syndrome and Cancer: Understanding the Risk Factors
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Dissecting Molecular differences between EGFR Exon 19 deletion and Exon 21 L858R Mutations
2.
Untangling The Best Treatment Approaches For ALK Positive Lung Cancer - Part II
3.
Optimizing Treatment Options in Advanced Urothelial Carcinoma
4.
A Comprehensive Guide to First Line Management of ALK Positive Lung Cancer - Part V
5.
A Comprehensive Guide to First Line Management of ALK Positive Lung Cancer - Part VIII
Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
To get started please enter your email ID
Welcome to Hidoc Dr.
Join to enhance your clinical skills and gain specialized in-depth medical knowledge